How to Actually Use the Global Private Equity Report Without Losing Your Mind
The Global Private Equity Report compiles deal flow data, LBO model outputs, and market multiples across regions. Most people treat it like a magic oracle. It isn't. It's a dataset that needs serious cleaning before it tells you anything useful. I've spent years working with PE firms and the report is one of those tools everyone cites but almost nobody applies correctly. Here's the thing nobody tells you. The report's raw numbers come from different methodologies depending on the region. North American figures use trailing twelve-month EBITDA adjustments while European entries often stick to reported statutory earnings. If you mash them together without normalizing, your multiples will be off by 10-15%. I learned this the hard way when a client wanted me to compare a UK manufacturing acquisition against a Texas software deal using the raw report data. The comps looked identical on paper. Once I adjusted for working capital differences and non-recurring restructuring charges, the UK deal was trading at a completely different value tier. Took me three days to catch it.
Getting the Global Private Equity Report and Setting It Up
Most firms access this through institutional data platforms like PitchBook, Preqin, or Capital IQ. If you don't have a subscription, some universities and smaller funds use pooled resources or third-party brokers who repackage the data. Download the raw CSV or Excel export, not the pre-formatted PDF summary. The PDF version filters out so much granular data that you lose the ability to cross-reference properly. Once you have the raw file, your first step is checking the methodology notes for each column. The report changes its calculation approach between versions, sometimes without clear documentation. I've seen sectors get reclassified mid-report. A healthcare company might shift from the pharmaceuticals bucket to medical devices depending on how the analyst classified their primary revenue stream. This matters because multiples vary wildly between those sub-sectors.
What the Numbers Actually Mean in Practice
The core sections break down into transaction history, fund performance metrics, and sector valuations. Transaction history shows actual deals with purchase prices, leveraged returns, and hold periods. Fund performance gives you IRR and MOIC data across vintage years. Sector valuations map current multiples against historical ranges. Most people fixate on the average multiples and stop there. That's where you miss the distribution. A median multiple tells you nothing about the dispersion in a given sector. I once saw a consumer discretionary deal priced at 14x EBITDA when the report's average for that sector sat at 11x. The buyer was confident until I pulled the transaction comps and showed that every other deal in that range involved companies with recurring revenue models. This particular target had lumpy contract-based revenue. The multiple looked justified on paper but the risk profile was completely different. When you're running your own LBO model off this data, don't just plug in the headline multiple. Look at the exit multiple assumption that other acquirers actually used. The report sometimes lists the entry multiple but the exit multiple tells you what the market actually paid when those companies eventually flipped. Those two numbers together give you the real return story.
Get the Full Details
Common Mistakes That Waste Time
People typically make three errors. First, they assume the report covers all of private equity when it skews heavily toward middle-market and large-cap transactions. Deals under 50 million in enterprise value are either missing or severely underrepresented depending on which data provider's version you're using. Second, they don't adjust for dry powder. When the report shows elevated multiples in a sector, that might reflect competition from massive uninvested capital rather than genuine fundamental improvement. Third, they ignore the vintaging problem. Fund performance from 2021 looks completely different from 2019 data because the cost of capital environment shifted dramatically between those years. My workaround for the vintage issue is to always group by investment period rather than reporting period. The report sometimes lists deals based on when they were published rather than when capital actually deployed. Running your analysis by deployment date instead of publication date usually corrects at least half the distortion in the data.
How to Extract Real Value From It
Create a normalized comparison spreadsheet. Pull the transaction data, strip out the noise, and rebuild the multiples yourself using consistent EBITDA definitions across all entries. This takes about forty-five minutes to an hour per sector if you're working with a typical dataset, but it saves you weeks of bad decisions down the line. Use the fund performance section to stress-test your own return assumptions rather than copying them directly. If the median fund in your target sector delivered a 22% net IRR over a seven-year period, ask yourself whether your model is being too conservative or too aggressive compared to that benchmark. The report gives you a reference point, not a target to hit. Track the carry waterfalls in the fund performance section. The headline IRR numbers don't show you where the actual money flows. A fund might report 25% gross IRR but the carried interest calculation could eat nearly half of those returns at the partner level. Understanding the fee structure behind the performance data helps you evaluate whether a sponsor's track record is as strong as the headline number suggests.
One last thing. The report has a blind spot when it comes to secondary transactions. If you're analyzing a buyout fund that's primarily exiting through secondaries rather than IPOs or trade sales, the data becomes unreliable. Secondary pricing follows a different logic than primary exits. The multiples compress faster and the hold period calculations break down. I always cross-reference secondary-heavy funds with direct outreach to the GP before relying on the report's numbers for those particular cases.
